Rimegepant BHV-3500

Background

Vlad Coric, M.D., Chief Executive Officer of Biohaven, commented, "Royalty Pharma has established itself as an industry leader in investing in late stage biopharmaceutical products. This transaction will allow us to fully fund Biohaven's current pipeline portfolio through the end of 2019 and demonstrates the value of our late-stage CGRP receptor antagonist products in migraine." Dr. Coric added, "We are excited that Royalty Pharma will be joining as investors in Biohaven and look forward to their participation as we continue to advance our product development candidates into the clinic with the goal of bringing new novel treatments to patients in areas of high unmet need."

About Rimegepant
Rimegepant is Biohaven's orally-dosed CGRP receptor antagonist, which the Company is developing as a treatment for migraine. Rimegepant represents a novel mechanism that targets the underlying pathophysiology of migraine without causing vasoconstriction.

About BHV-3500
BHV-3500, the second product candidate in Biohaven’s CGRP platform, is a highly soluble small molecule CGRP receptor antagonist. It is also structurally distinct from rimegepant. The chemical properties of BHV-3500 make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.

Therapeutic Area

Acute Treatment
Prevention of Migraine

Acquisition Date

Jun 2018

Marketer

Seller